Global Medicinal Chemistry for Drug Discovery Market, By Process (Target Selection, Target Validation, Hit-To-Lead Identification, Lead Optimization, Candidate Validation), Design (Fragment-Based Variation, Structure-Based Drug Design, Diversity Oriented Synthesis, Chemogenomics, Natural Products, Others), Drug Type (Small Molecules, Biologics), Therapeutic Area (Oncology, Neurology, Infectious and Immune System Diseases, Cardiovascular Diseases, Digestive System Diseases, Others), End User (Contract Research Organization, Pharmaceuticals and Biotechnology Companies, Academic and Research Institutes, Others) – Industry Trends and Forecast to 2030.
Medicinal Chemistry for Drug Discovery Market Analysis and Size
The key factors driving the medicinal chemistry for drug discovery market are increasing applications in clinical diagnosis and the growing demand for diagnosing rare diseases. Medicinal chemistry for drug discovery comprises features such increasing need for safe and effective drugs will impact in launching new product by the manufactures into the market which enhance its demand as well as increase in research and development investment for discovery and development of novel drug molecules leads to the market growth. Currently various research studies are taking place which is expected to provide various other opportunities in the medicinal chemistry for drug discovery market. The development of advanced laboratory techniques, computational tools, and artificial intelligence for drug discovery accelerates the process and increases the likelihood of success. Moreover, advancements in biotechnology, genomics, and proteomics has enabled a better understanding of disease mechanisms. This knowledge is crucial for designing drugs with greater specificity and effectiveness. This, in turn, will extend profitable opportunities for the market players in the forecast period of 2023 to 2030 by enabling more comprehensive and cost-effective sequencing.
Moreover, the growing adoption of personalized medicine is further estimated to provide potential opportunities for the growth of the medicinal chemistry for drug discovery market in the forecast period. However, technical risks in drug discovery and lack of trained skilled professionals expected to restraint the market growth in the forecast period.
Data Bridge Market Research analyzes that the global medicinal chemistry for drug discovery market which was USD 5,379.22 million in 2022, is likely to reach USD 14,306.98 million by 2030, and is expected to undergo a CAGR of 13.60% during the forecast period. “Hospitals and Clinics” dominates the end user segment of the medicinal chemistry for drug discovery market due to the growing demand for products. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Report Scope and Market Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2023 to 2030
|
|
Base Year
|
2022
|
|
Historic Years
|
2021 (Customizable to 2015-2020)
|
|
Quantitative Units
|
Revenue in USD Million, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
By Process (Target Selection, Target Validation, Hit-To-Lead Identification, Lead Optimization, Candidate Validation), Design (Fragment-Based Variation, Structure-Based Drug Design, Diversity Oriented Synthesis, Chemogenomics, Natural Products, Others), Drug Type (Small Molecules, Biologics), Therapeutic Area (Oncology, Neurology, Infectious and Immune System Diseases, Cardiovascular Diseases, Digestive System Diseases, Others), End User (Contract Research Organization, Pharmaceuticals and Biotechnology Companies, Academic and Research Institutes, Others)
|
|
Countries Covered
|
U.S., Canada and Mexico, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific, Saudi Arabia, U.A.E., South Africa, Egypt, Israel, Rest of Middle East and Africa, Brazil, Argentina and Rest of South America
|
|
Market Players Covered
|
Eurofins Scientific (Germany), Covance Inc. (U.S.), WuXi AppTec (China), Thermo Fisher Scientific, Inc. (U.S.), Evotec SE (Germany), Piramal Pharma Solutions (India), Pfizer, Inc. (U.S.), Certara (U.S.), Sygnature Discovery Limited (U.K.), Malvern Panalytical Ltd (U.K.), Jubilant Biosys Ltd. (India), Taros Chemicals GmbH & Co. KG (Germany), GenScript Biotech Corporation (U.S.), Nereid Therapeutics Inc. (U.S.), BioBlocks, Inc. (U.S.), Charnwood Molecular LTD (U.K.), Domainex (U.K.), Aurigene Pharmaceutical Services Ltd. (a subsidiary of Dr. Reddy’s Laboratories Ltd.) (India), Selvita (U.S.), Nanosyn (U.S.)
|
|
Market Opportunities
|
|
Market Definition
Medicinal chemistry is the interdisciplinary field of science that involves a team of scientists (including synthetic organic chemists, analytical chemists, biologists, toxicologists, pharmacologists, microbiologists, and biopharmacists) working together for drug discovery, design, development and synthesis of new pharmaceuticals. Moreover, the contribution of medicinal chemistry is not confined just to the discovery stage. It carries its purpose along the entire spectrum of clinical development. Each and every stage of clinical development involves surplus amounts of formulated drugs for studying potential benefits in human trials. With time the chemical methods adopted for the discovery of the molecules have also undergone changes leading to the development of technologies such as combinatorial chemistry (combichem), microwave assisted organic synthesis (MAOS) and high-throughput (HTS) biological screening.
Global Medicinal Chemistry for Drug Discovery Market Dynamics
Drivers
- Increasing disease burden
The most major element driving this market's growth is the rising prevalence of various diseases, including cancer, cardiovascular diseases, and infectious diseases, drives the need for new and more effective drugs. Medicinal chemistry plays a critical role in drug discovery for these conditions which is expected to drive the market in the forecast period
- Rising number of geriatric population
The global aging population increases the demand for pharmaceuticals. Elderly individuals often require medications for chronic diseases and age-related conditions, leading to a need for innovative drug discovery. The increasing geriatric population is associated with a higher prevalence of these conditions, leading to increased demand for drug discovery. Thus, expanding geriatric population worldwide is predicted to favour the market
- Rising healthcare expenditure
Increasing healthcare spending by governments and individuals can support drug discovery efforts and drive market growth. Moreover, investment from governments, private organizations, and pharmaceutical companies in research and development (R&D) for drug discovery can drive advancements in medicinal chemistry.
Opportunities
- Technological advancement of therapies for the treatment
The development of advanced laboratory techniques, computational tools, and artificial intelligence for drug discovery accelerates the process and increases the likelihood of success. Moreover, advancements in biotechnology, genomics, and proteomics has enabled a better understanding of disease mechanisms. This knowledge is crucial for designing drugs with greater specificity and effectiveness. This, in turn, will extend profitable opportunities for the market players in the forecast period of 2023 to 2030 by enabling more comprehensive and cost-effective sequencing.
Restraints/Challenges
- High cost of research
On the other hand, the high Development cost of research, clinical trials, and regulatory compliance can be a significant restraint, particularly for smaller pharmaceutical companies and startups which is further projected to impede the growth of the medicinal chemistry for drug discovery market in the targeted period. Moreover, technical risks in drug discovery and lack of trained skilled professionals expected to further challenge the growth of the medicinal chemistry for drug discovery market.
This medicinal chemistry for drug discovery market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the medicinal chemistry for drug discovery market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Recent Development
- In November 2021, Jubilant Biosys Limited expanded its facilities in order to support the drug discovery chemistry services and in-vitro ADME services. Moreover, the company is providing services for Turning Point Therapeutics Inc. for small molecule oncology research programs. Through this expansion the company has leveraged its offering which allowed it to penetrate its root in global medicinal chemistry for drug discovery market
- In February 2021, Eurofins acquired Beacon Discovery for its years of experience in drug discovery and development and innovative approach. Beacon Discovery is also well known for its profound expertise in GPCR (G-Protein Coupled Receptor) research. Through this acquisition the company has strengthen its presence in global medicinal chemistry for drug discovery market
Global Medicinal Chemistry for Drug Discovery Market Scope
The medicinal chemistry for drug discovery market is segmented on the process, design, drug type, therapeutic area and end user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Process
- Target Selection
- Target Validation
- Hit-To-Lead Identification
- Lead Optimization
- Candidate Validation
Design
- Fragment-Based Variation
- Structure-Based Drug Design
- Diversity Oriented Synthesis
- Chemogenomics
- Natural Products
- Others
Drug Type
- Small Molecules
- Biologics
Therapeutic Area
- Oncology
- Neurology
- Infectious and Immune System Diseases
- Cardiovascular Diseases
- Digestive System Diseases
- Others
End User
- Contract Research Organization
- Pharmaceuticals and Biotechnology Companies
- Academic and Research Institutes
- Others
Global Medicinal Chemistry for Drug Discovery Market Regional Analysis/Insights
The medicinal chemistry for drug discovery market is analysed and market size insights and trends are provided by country, process, design, drug type, therapeutic area and end user as referenced above.
The countries covered in the medicinal chemistry for drug discovery market report are U.S., Canada and Mexico, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, rest of Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, rest of Asia-Pacific, Saudi Arabia, U.A.E., South Africa, Egypt, Israel, rest of Middle East and Africa, Brazil, Argentina and rest of South America.
North America is expected to dominate the medicinal chemistry for drug discovery market due to increasing clinical trials and research development for prevention of chronic diseases in the region.
Asia-Pacific is expected to grow at the highest growth rate during the forecast period of 2023 to 2030 due to increasing initiatives for research on rare diseases and orphan drugs in the region in the coming years.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Healthcare Infrastructure growth Installed base and New Technology Penetration
The medicinal chemistry for drug discovery market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for medicinal chemistry for drug discovery market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the medicinal chemistry for drug discovery market. The data is available for historic period 2010-2020.
Competitive Landscape and Global Medicinal Chemistry for Drug Discovery Market Share Analysis
The medicinal chemistry for drug discovery market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to medicinal chemistry for drug discovery market.
Some of the major players operating in the medicinal chemistry for drug discovery market are:
- Eurofins Scientific (Germany)
- Covance Inc. (U.S.)
- WuXi AppTec (China)
- Thermo Fisher Scientific, Inc. (U.S.)
- Evotec SE (Germany)
- Piramal Pharma Solutions (India)
- Pfizer, Inc. (U.S.)
- Certara (U.S.)
- Sygnature Discovery Limited (U.K.)
- Malvern Panalytical Ltd (U.K.)
- Jubilant Biosys Ltd. (India)
- Taros Chemicals GmbH & Co. KG (Germany)
- GenScript Biotech Corporation (U.S.)
- Nereid Therapeutics Inc. (U.S.)
- BioBlocks, Inc. (U.S.)
- Charnwood Molecular LTD (U.K.)
- Domainex (U.K.)
- Aurigene Pharmaceutical Services Ltd. (a subsidiary of Dr. Reddy’s Laboratories Ltd.) (India)
- Selvita (U.S.)
- Nanosyn (U.S.)
SKU-